Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GDC-0810

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug GDC-0810?

GDC-0810 is an investigational drug.

There have been 165 clinical trials for GDC-0810. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Leukemia. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are twelve US patents protecting this investigational drug and one hundred and four international patents.

Recent Clinical Trials for GDC-0810
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to HormNational Cancer Institute (NCI)Phase 1/Phase 2
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the BonesNational Cancer Institute (NCI)Phase 2
A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast CancerHoffmann-La RochePhase 2/Phase 3

See all GDC-0810 clinical trials

Clinical Trial Summary for GDC-0810

Top disease conditions for GDC-0810
Top clinical trial sponsors for GDC-0810

See all GDC-0810 clinical trials

US Patents for GDC-0810

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0810   Start Trial Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer Genentech, Inc. (South San Francisco, CA)   Start Trial
GDC-0810   Start Trial Estrogen receptor mutations and uses thereof FOUNDATION MEDICINE, INC. (Cambridge, MA)   Start Trial
GDC-0810   Start Trial Estrogen receptor modulators and uses thereof Aragon Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
GDC-0810   Start Trial Estrogen receptor modulators and uses thereof Aragon Pharmaceuticals, Inc. (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0810

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0810 Australia 2014358850 2033-12-06   Start Trial
GDC-0810 Canada 2932106 2033-12-06   Start Trial
GDC-0810 China 105916501 2033-12-06   Start Trial
GDC-0810 European Patent Office 3089747 2033-12-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.